# Safety, Tolerability and Immunogenicity of INO-4500 in Healthy Volunteers

> **NCT03805984** · PHASE1 · COMPLETED · sponsor: **Inovio Pharmaceuticals** · enrollment: 60 (actual)

## Conditions studied

- Lassa Fever

## Interventions

- **DRUG:** INO-4500
- **DRUG:** Placebo
- **DEVICE:** CELLECTRA® 2000

## Key facts

- **NCT ID:** NCT03805984
- **Lead sponsor:** Inovio Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-05-09
- **Primary completion:** 2020-10-21
- **Final completion:** 2020-10-21
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2020-11-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03805984

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03805984, "Safety, Tolerability and Immunogenicity of INO-4500 in Healthy Volunteers". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT03805984. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*